Myeloid ATF3 Protects Against Liver Fibrosis by Modulating the Extracellular Microenvironment and Macrophage Inflammatory Signaling
The FASEB Journal · 2026
DOI: 10.1096/fj.202502142rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Hao Ling und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Activating Transcription Factor 3, Liver Cirrhosis, Signal Transduction, Macrophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Activating transcription factor 3 (ATF3) is a stress‐inducible transcription factor that regulates inflammatory responses; however, its cell‐type‐specific role in liver fibrosis remains incompletely defined. We investigated the function of myeloid cell‐specific ATF3 in carbon tetrachloride (CCl 4 )‐induced liver fibrosis. ATF3 induction was confirmed in bone marrow‐derived macrophages following lipopolysaccharide stimulation in vitro. Myeloid‐specific Atf3 knockout mice ( Atf3 fl/fl LysM ‐Cre+) and littermate controls were subjected to CCl 4 treatment to determine the impact of ATF3 loss in vivo. Myeloid ATF3 deficiency significantly exacerbated CCl 4 ‐induced liver injury, reflected by elevated serum ALT and AST levels, increased collagen deposition, and higher fibrosis scores. ATF3 loss enhanced hepatic stellate cell activation, as evidenced by increased α‐SMA protein and elevated Acta2 and Col1a1 expression. Although total macrophage abundance was unchanged, ATF3 deficiency shifted macrophage composition toward increased Ly6C+ infiltrating monocyte‐derived macrophages and reduced Kupffer cell markers. Mechanistically, Atf3‐deficient livers displayed increased inflammatory chemokine expression ( Ccl3 , Ccl4 , Ccl5 , Ccl8 ), reduced matrix metalloproteinases ( Mmp2 , Mmp8 , and Mmp9 ), increased tissue inhibitor of metalloproteinases 1 ( Timp1 ), and enhanced activation of transforming growth factor‐beta1 (TGF‐β1)/SMAD signaling. These findings identify myeloid ATF3 as a protective regulator that restrains inflammatory amplification and extracellular matrix accumulation during liver fibrosis. Modulation of ATF3‐dependent pathways may represent a potential therapeutic strategy for fibrotic liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Department of Orthopedics, Qujing First People's Hospital, Affiliated Qujing Hospital of Kunming Medical University, Qujing, Yunnan, China.
- University Clinic for General, Visceral and Transplantation Surgery, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.
ORCID-Profile: Hao Ling
Zitieren
APA
Ling, H., Hu, Y., Onyuru, J., Shi, J., Steffani, M., Wang, J., Wasmaier, L., Schulze, S., Märitz, N., Xin, Z., Friess, H., Holzmann, B., Hüser, N., Stoess, C., & Hartmann, D. (2026). Myeloid ATF3 Protects Against Liver Fibrosis by Modulating the Extracellular Microenvironment and Macrophage Inflammatory Signaling. The FASEB Journal. https://doi.org/10.1096/fj.202502142rr
Vancouver
Ling H, Hu Y, Onyuru J, Shi J, Steffani M, Wang J, et al. Myeloid ATF3 Protects Against Liver Fibrosis by Modulating the Extracellular Microenvironment and Macrophage Inflammatory Signaling. The FASEB Journal. 2026. doi:10.1096/fj.202502142rr
BibTeX
@article{Ling2026,
author = {Ling, Hao and Hu, Yanzhu and Onyuru, Janset and Shi, Jing and Steffani, Marcella and Wang, Jianye and Wasmaier, Lena and Schulze, Sarah and Märitz, Nadja and Xin, Zhengyi and Friess, Helmut and Holzmann, Bernhard and Hüser, Norbert and Stoess, Christian and Hartmann, Daniel},
title = {Myeloid ATF3 Protects Against Liver Fibrosis by Modulating the Extracellular Microenvironment and Macrophage Inflammatory Signaling},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202502142rr}
}
EUVIMED